EYEPOINT PHARMACEUTICALS INC (EYPT) Stock Fundamental Analysis
USA - NASDAQ:EYPT - US30233G2093 - Common Stock
11.645 USD
+0.29 (+2.6%)
11.54 USD
-0.11 (-0.9%)
Taking everything into account, EYPT scores 4 out of 10 in our fundamental rating. EYPT was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for EYPT as it has an excellent financial health rating, but there are worries on the profitability. EYPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year EYPT has reported negative net income.
EYPT had a negative operating cash flow in the past year.
In the past 5 years EYPT always reported negative net income.
EYPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -81.75%, EYPT is doing worse than 73.30% of the companies in the same industry.
With a Return On Equity value of -102.78%, EYPT is not doing good in the industry: 60.73% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.75% | ||
| ROE | -102.78% | ||
| ROIC | N/A |
ROA(3y)-35.96%
ROA(5y)-35.91%
ROE(3y)-57.18%
ROE(5y)-89.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EYPT's Gross Margin of 94.08% is amongst the best of the industry. EYPT outperforms 96.34% of its industry peers.
EYPT's Gross Margin has been stable in the last couple of years.
EYPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.5%
GM growth 5Y1.04%
2. Health
2.1 Basic Checks
EYPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EYPT has been increased compared to 1 year ago.
The number of shares outstanding for EYPT has been increased compared to 5 years ago.
There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 3.09 indicates that EYPT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.09, EYPT is in the better half of the industry, outperforming 69.63% of the companies in the same industry.
There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.09 |
ROIC/WACCN/A
WACC8.92%
2.3 Liquidity
EYPT has a Current Ratio of 7.18. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.18, EYPT is in the better half of the industry, outperforming 74.35% of the companies in the same industry.
EYPT has a Quick Ratio of 7.11. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
EYPT has a better Quick ratio (7.11) than 74.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.18 | ||
| Quick Ratio | 7.11 |
3. Growth
3.1 Past
The earnings per share for EYPT have decreased strongly by -49.50% in the last year.
The Revenue has decreased by -7.38% in the past year.
Measured over the past years, EYPT shows a quite strong growth in Revenue. The Revenue has been growing by 16.26% on average per year.
EPS 1Y (TTM)-49.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.41%
Revenue 1Y (TTM)-7.38%
Revenue growth 3Y5.42%
Revenue growth 5Y16.26%
Sales Q2Q%-90.82%
3.2 Future
Based on estimates for the next years, EYPT will show a very strong growth in Earnings Per Share. The EPS will grow by 20.88% on average per year.
The Revenue is expected to grow by 62.86% on average over the next years. This is a very strong growth
EPS Next Y-34.72%
EPS Next 2Y-15.42%
EPS Next 3Y-7.97%
EPS Next 5Y20.88%
Revenue Next Year-14.15%
Revenue Next 2Y-38.89%
Revenue Next 3Y27.49%
Revenue Next 5Y62.86%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EYPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EYPT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EYPT's earnings are expected to decrease with -7.97% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.42%
EPS Next 3Y-7.97%
5. Dividend
5.1 Amount
No dividends for EYPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.645
+0.29 (+2.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners99.52%
Inst Owner Change-1%
Ins Owners3.51%
Ins Owner Change-0.07%
Market Cap939.98M
Revenue(TTM)42.34M
Net Income(TTM)-205.75M
Analysts85.26
Price Target35.1 (201.42%)
Short Float %10.56%
Short Ratio7.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.37%
Min EPS beat(2)-6.19%
Max EPS beat(2)-4.55%
EPS beat(4)1
Avg EPS beat(4)-8.28%
Min EPS beat(4)-25.16%
Max EPS beat(4)2.78%
EPS beat(8)3
Avg EPS beat(8)-4.09%
EPS beat(12)5
Avg EPS beat(12)-21.87%
EPS beat(16)8
Avg EPS beat(16)-14.5%
Revenue beat(2)0
Avg Revenue beat(2)-46.33%
Min Revenue beat(2)-71.55%
Max Revenue beat(2)-21.1%
Revenue beat(4)2
Avg Revenue beat(4)27.57%
Min Revenue beat(4)-71.55%
Max Revenue beat(4)200.52%
Revenue beat(8)5
Avg Revenue beat(8)22.34%
Revenue beat(12)7
Avg Revenue beat(12)16.22%
Revenue beat(16)9
Avg Revenue beat(16)12.42%
PT rev (1m)-2.17%
PT rev (3m)6.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-31.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 22.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.7 | ||
| P/tB | 4.7 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.99
EYN/A
EPS(NY)-3.08
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.61
OCFYN/A
SpS0.52
BVpS2.48
TBVpS2.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.75% | ||
| ROE | -102.78% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.08% | ||
| FCFM | N/A |
ROA(3y)-35.96%
ROA(5y)-35.91%
ROE(3y)-57.18%
ROE(5y)-89.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.5%
GM growth 5Y1.04%
F-Score4
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 128.87% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.18 | ||
| Quick Ratio | 7.11 | ||
| Altman-Z | 3.09 |
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)367.17%
Cap/Depr(5y)224.18%
Cap/Sales(3y)7.38%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.41%
EPS Next Y-34.72%
EPS Next 2Y-15.42%
EPS Next 3Y-7.97%
EPS Next 5Y20.88%
Revenue 1Y (TTM)-7.38%
Revenue growth 3Y5.42%
Revenue growth 5Y16.26%
Sales Q2Q%-90.82%
Revenue Next Year-14.15%
Revenue Next 2Y-38.89%
Revenue Next 3Y27.49%
Revenue Next 5Y62.86%
EBIT growth 1Y-86.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.29%
EBIT Next 3Y20.92%
EBIT Next 5YN/A
FCF growth 1Y-2419.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1802.28%
OCF growth 3YN/A
OCF growth 5YN/A
EYEPOINT PHARMACEUTICALS INC / EYPT FAQ
What is the ChartMill fundamental rating of EYEPOINT PHARMACEUTICALS INC (EYPT) stock?
ChartMill assigns a fundamental rating of 4 / 10 to EYPT.
What is the valuation status for EYPT stock?
ChartMill assigns a valuation rating of 0 / 10 to EYEPOINT PHARMACEUTICALS INC (EYPT). This can be considered as Overvalued.
What is the profitability of EYPT stock?
EYEPOINT PHARMACEUTICALS INC (EYPT) has a profitability rating of 1 / 10.
What is the financial health of EYEPOINT PHARMACEUTICALS INC (EYPT) stock?
The financial health rating of EYEPOINT PHARMACEUTICALS INC (EYPT) is 8 / 10.
What is the earnings growth outlook for EYEPOINT PHARMACEUTICALS INC?
The Earnings per Share (EPS) of EYEPOINT PHARMACEUTICALS INC (EYPT) is expected to decline by -34.72% in the next year.